Eravacycline Application Scope

Intravenous treatment of complicated intra-abdominal infections (cIAIs) in adults caused by susceptible organisms (e.g., E. coli, K. pneumoniae, Enterococcus spp., S. aureus, Bacteroides spp., etc.)

Characteristics

Ingredients: 50 mg eravacycline (equivalent to 63.5 mg eravacycline dihydrochloride) per single-dose vial (lyophilized powder)
Properties: Fully synthetic fluorocycline (tetracycline class), with broad-spectrum activity including many MDR Gram-negative, Gram-positive, and anaerobic bacteria
Packaging Specification: Single-dose lyophilized powder vial containing 50 mg eravacycline
Storage: See prescribing info for optimal storage; generally stored at controlled room temperature before reconstitution
Expiry Date: Per vial label (usually 2–3 years from manufacture; check package insert)
Executive Standard: Complies with FDA/EMA prescribing standards as defined in XERAVA’s label
Approval Number: FDA-approved on August 27, 2018 for cIAI
Date of Revision: See latest FDA label (2018; check your package information for updated revision dates)
Manufacturer: Marketed by Innoviva Specialty Therapeutics on behalf of Tetraphase Pharmaceuticals

Guidelines for the Use of Eravacycline

Dosage and Administration:
- Reconstitute vial and administer as IV infusion over ~60 minutes, every 12 hours
- Recommended dose: 1 mg/kg IV every 12 hours for 4–14 days, based on infection severity and clinical response
- Compatible with 0.9% sodium chloride; do not mix with other drugs
Adverse Reactions:
- Common (≥3%): Infusion site reactions (≈7.7%), nausea (≈6.5%), vomiting (≈3.7%)
- Others: Hives, difficulty breathing, diarrhea (including up to 2 months post-treatment), severe headaches, pancreatitis, photosensitivity, pseudotumor cerebri, elevated liver enzymes, BUN, and azotemia
Contraindications: Hypersensitivity to eravacycline, tetracycline-class antibiotics, or any excipient
Precautions:
- Allergic reactions: Risk of anaphylaxis—discontinue use if symptoms occur
- Tooth discoloration & enamel hypoplasia: Avoid during tooth development (pregnancy 2nd–3rd trimester, infants, children ≤8 years)
- Bone growth inhibition: Possible reversible effects on bone growth in young children/pregnant women
- Clostridioides difficile–associated diarrhea: Monitor for diarrhea during and up to 2 months post-therapy
- Photosensitivity, pseudotumor cerebri, liver/kidney function changes, pancreatitis: Monitor and discontinue if suspected
- Superinfection risk: May lead to fungal or resistant bacterial overgrowth; monitor and treat accordingly

Interactions

Drug Interactions:
CYP3A inducers: e.g., rifampin—may reduce eravacycline exposure; dose adjustments may be needed
Anticoagulants: Additive effect—monitor INR and adjust dose as needed
General tetracycline-like interactions: Avoid coadministration with antacids, iron, calcium-rich foods that inhibit absorption (if/when oral formulation used)

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.